Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback

Simply Wall St.01-22 14:36

AdvertisementWhy Akeso is on investors’ radars today Akeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605668469?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-22 14:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605668469","market":"us","top_or_hot":-1,"title":"Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Akeso is on investors’ radars today Akeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso (SEHK:9926) Valuation Check After Recent Share Price Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 14:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Akeso is on investors’ radars today Akeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348766576.USD","symbol_name":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","article_id":"2605668469","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605668469","pubTimestamp":1769063769,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Akeso is on investors’ radars today\nAkeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day return of 7.6% decline from its last close of HK$114. Investors are weighing these short term moves against its longer term record and the company’s current fundamentals.\nSee our latest analysis for Akeso.\nWhile the recent 1 day and 7 day share price returns are both in decline, Akeso’s 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","09926":"康方生物","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1161":"生物科技","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC"},"translate_title":"康方生物(SEHK：9926)近期股价回调后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9,"DCF":1},"content_text":"AdvertisementWhy Akeso is on investors’ radars today Akeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day return of 7.6% decline from its last close of HK$114. Investors are weighing these short term moves against its longer term record and the company’s current fundamentals. See our latest analysis for Akeso. While the recent 1 day and 7 day share price returns are both in decline, Akeso’s 1 year total shareholder return of 82.11% and 3 year total shareholder return of 138.49% suggest that longer term momentum has been stronger than its latest pullback. If Akeso’s moves have caught your attention, this could be a good moment to widen your watchlist with other healthcare stocks that might fit your investment style. With Akeso trading at HK$114 and indicators like analyst targets and intrinsic value estimates suggesting a sizeable gap, the key question is whether the current price is a genuine opportunity or if the market is already pricing in future growth. Price-to-Sales of 37.4x: Is it justified? On a P/S basis, Akeso looks expensive, with the shares trading at 37.4x sales compared with peers and fair value benchmarks that point to a lower level. The P/S ratio compares the company’s market value to its revenue. It is often used for businesses that are still loss making, like many biopharma names. At 37.4x, investors are paying a high price for each HK$ of current sales, which reflects strong expectations for future revenue and, eventually, profitability. Against the Hong Kong Biotechs industry average P/S of 13.5x and a fair P/S estimate of 18.2x, Akeso’s 37.4x multiple is more than double both reference points. That indicates the current market valuation is rich relative to sector peers and to the level the P/S ratio could move toward if sentiment or expectations cool. Explore the SWS fair ratio for Akeso Result: Price-to-Sales of 37.4x (OVERVALUED) However, investors also need to factor in Akeso’s HK$846.006 loss and its dependence on the successful development and commercialization of a broad pipeline of antibody drugs. Find out about the key risks to this Akeso narrative. Another View: DCF suggests the price may be too low While the 37.4x P/S ratio makes Akeso look expensive, our DCF model points in the opposite direction. At HK$114, the shares are trading 45.9% below an estimated future cash flow value of HK$210.6. This frames the recent pullback very differently. Which signal do you trust more: current sales or long term cash flows? Look into how the SWS DCF model arrives at its fair value. 9926 Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Akeso for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 881 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Akeso Narrative If you see the numbers differently or prefer to work through the data yourself, you can build your own view in a few minutes with Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Akeso. Looking for more investment ideas? If Akeso is on your radar, do not stop there. Use the Simply Wall Street Screener to spot other clear ideas before the crowd pays attention.  Hunt for potential mispriced opportunities by checking out these 881 undervalued stocks based on cash flows built from detailed cash flow analysis. Tap into the growth story in artificial intelligence with these 23 AI penny stocks that are aligned with this fast changing theme. Target dependable cash returns by scanning these 13 dividend stocks with yields > 3% that offer yields above 3% and may complement your portfolio income goals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605668469","isCrawlerRequest":true}